Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "therapeutic"

1505 News Found

Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease
Drug Approval | January 07, 2025

Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease

Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A


Nano-formulation of darkness hormone could be therapeutic solution for Parkinson's disease
News | January 04, 2025

Nano-formulation of darkness hormone could be therapeutic solution for Parkinson's disease

Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain


SVU to organise International Conference on Clinical Translation of Biomaterial-based Therapeutics and Devices on 6-7 Feb, 2025
News | December 26, 2024

SVU to organise International Conference on Clinical Translation of Biomaterial-based Therapeutics and Devices on 6-7 Feb, 2025

The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”


SPARC signs LoI with UCSF and Tiller Therapeutics for pre-clinical oncology asset and associated IP
News | December 17, 2024

SPARC signs LoI with UCSF and Tiller Therapeutics for pre-clinical oncology asset and associated IP

SPARC to receive 55% equity in Tiller Therapeutics


AbbVie completes acquisition of Aliada Therapeutics
News | December 12, 2024

AbbVie completes acquisition of Aliada Therapeutics

Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease


Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease
Biotech | December 07, 2024

Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease

GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization


AbbVie and EvolveImmune Therapeutics collaborate to develop next-generation cancer biotherapeutics
News | November 05, 2024

AbbVie and EvolveImmune Therapeutics collaborate to develop next-generation cancer biotherapeutics

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer


AbbVie to acquire Aliada Therapeutics
News | November 01, 2024

AbbVie to acquire Aliada Therapeutics

Strengthening focus in Alzheimer's disease and neuroscience pipeline


Alkem enters into licensing agreement with BioTherapeutics
News | October 11, 2024

Alkem enters into licensing agreement with BioTherapeutics

Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings


BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months
Clinical Trials | September 27, 2024

BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months

At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts